Avagenesis and Avapecia Stem Cell Platform in Top Ranked United States Medical Centre

CALGARY, AB and RICHMOND, BC / ACCESSWIRE / May 26, 2016 / Avagenesis Corp. (TSX-V: VVA) and Avapecia Life Sciences Corp. (CNSX: VVS) (“Company” or the “Companies”) are pleased to announce the installation of multiple systems with one of the top three hospitals in the United States, as ranked by U.S. News & World Report’s “2015-16 Best Hospitals Honor Roll”. A Memorandum of Understanding (“Agreement”) supports the collaboration.

The Agreement confirms and validates the collaboration with this top ranked hospital and its launch of multi-therapy, multi-site regenerative medicine clinical trials that will use the Companies’ adipose stem cell isolation platform. The platform system produces a cost effective and highly potent regenerative biopharmaceutical stem cell product for multiple indications and conditions that have significant potential for use in stem cell therapies.

“The Agreement with this world renowned medical centre is a significant milestone towards enabling the rapid expansion of translational medical research, standardized, high quality, global multi-centre clinical trials and the application and adoption of the safe, affordable, and point of care use of autologous cellular therapies in regenerative medicine,” stated Dr. Peter Neweduk, CEO of Avapecia.

“At present, the handling and processing of live adipose tissue to isolate the component stem cells is expensive, inefficient, of relatively poor and inconsistent quality and, in many cases, falls short of required safety standards. We believe that the resulting poor quality of cellular therapy treatments has damaged the reputation of cellular therapy. This has limited autologous (non embryonic) cellular therapy solutions and slowed widespread medical adoption of regenerative medicine applications,” stated Norm Tsui, CEO of Avagenesis. “We designed this system to address these issues. Our highly automated, point of care system offers researchers and clinicians a far superior alternative to existing cell processing solutions not only because it is much more efficient (48 minutes total cell processing time), affordable and simple to operate, but because it produces a standardized cellular product. The result is that the adipose tissue we process creates virtually the same quality isolated stem cell products whether a medical professional is operating the platform in Beijing, New York, Berlin, Sao Paulo, or Dubai or in a small clinic or large research facility. Finally, a standardized, cellular starting point for researchers and clinicians facilitates worldwide comparability of outcomes.”

About the U.S. News & World Report’s Best Hospitals (http://health.usnews.com/best-hospitals)

U.S. News evaluates data for nearly 5,000 hospitals and results from surveys of more than 140,000 physicians to rank the best centres in 16 adult specialties from cancer to urology. Death rates, patient safety and hospital reputation were a few of the many factors considered. Only 137 hospitals were nationally ranked in a specialty. The Honor Roll features the 15 Best Hospitals in the United States.

About Avagenesis Corp. (http://www.avagenesis.com)

Avagenesis is a biotechnology company engaged in the commercialization of licensed cell isolation medical technologies for use in regenerative medical aesthetics, wound management and non-healing wounds, cardiovascular and heart diseases, peripheral arterial disease, critical limb ischemia or diabetic leg, hepatic disease and kidney disease.

About Avapecia Life Sciences Corp. (http://www.avapecia.com)

Avapecia is a biotechnology company engaged in the research, development and commercialization of regenerative stem cell technologies and therapy solutions for use in urogynaecology, urology, hair loss (prevention, maintenance, and regeneration), gastrointestinal diseases, respiratory medicine, neurodegenerative diseases, ophthalmology, spinal cord injuries and certain autoimmune diseases. Avapecia’s bioprocessing platform provides third party validated and standardized isolation of safe, high quality, viable, and potent stem cells from a patient’s own fat, or adipose tissue, for use in current and future cell therapy applications.

Neither the TSX Venture Exchange or Canadian Securities Exchange nor their respective regulation services providers (as that term is defined in their respective policies) accepts responsibility for the adequacy or accuracy of this press release.

Cautionary Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could,” “intend,” “expect,” “believe,” “will,” “projected,” “likely,” “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on current belief or assumptions as to the outcome and timing of such future events. Actual future results and developments may differ materially from those contemplated by these statements depending on, among other things, the risk that the Company may not successfully transition to a clinical stage company and successfully execute its development and commercialization activities. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the Company. Readers are cautioned that the above list of risk factors is not exhaustive. The forward-looking information contained in this press release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

Further Information

For further information, please contact:
Avagenesis Corp. or Avapecia Life Sciences Corp.
Alan Tam, CPA, CA
Chief Financial Officer
Telephone: (604) 377-7575

SOURCE: Avagenesis Corp. and Avapecia Life Sciences Corp.

ReleaseID: 440453